)
Aurobindo Pharma today said it has received the final approval from the US Food and Drug Administration (USFDA) to manufacture and market Repaglinide tablets.
The product is ready for launch, it said. The Repaglinide is a generic equivalent of Novo Nordisk Inc's Prandin tables, which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes, according to a company press release.
The market size of the product is estimated to be $274 million for the twelve months ending November 2013, it said.
Shares of Aurobindo Pharma were trading at Rs 433 per scrip in the afternoon trade, down 0.74% from previous close, on the BSE.
